Serum Myostatin Predicts the Risk of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis: A Multicenter Study
Authors:
- Ji Hyun KimJKJi Hyun Kim
- Seong Hee KangSKSeong Hee Kang
- Minjong LeeMLMinjong Lee
- Gi Soo YounGYGi Soo Youn
- Tae Suk KimTKTae Suk Kim
- Baek Gyu JunBJBaek Gyu Jun
- Moon Young KimMKMoon Young Kim
- Young Don KimYKYoung Don Kim
- Gab Jin CheonGCGab Jin Cheon
- Dong Joon KimDong Joon Kim
- Soon Koo BaikSBSoon Koo Baik
- Dae Hee ChoiDCDae Hee Choi
Open Access
Abstract
Background and Aim: Previous studies reported that serum myostatin is associated with sarcopenia. We aimed to elucidate the association between serum myostatin levels and hepatocellular carcinoma (HCC) development in patients with alcoholic liver cirrhosis (ALC). Methods: This retrospective, multicenter study assessed 1077 Asian ALC patients enrolled from 2007 to 2017. The primary endpoint was the development of HCC within 5 years. Cox proportional hazards model analyses were used to assess the association of serum myostatin levels and HCC development. The time-dependent areas under the receiver operating characteristic curve (AUROC) of serum myostatin for 5-year HCC development were calculated. Serum myostatin levels were measured using an enzyme-linked immunosorbent assay with samples collected on the index date. Results: During a median follow-up of 2.5 years, 5-year cumulative HCC incidence rates were 6.7% in the total population. The median level of serum myostatin was 3.3 ng/mL (interquartile, 2.1–5.2 ng/mL). The AUROC of serum myostatin for 5-year HCC development was 0.78 (95% confidence interval [CI], 0.76–0.81). In Cox proportional hazards model analyses, age, gender, platelet counts, and serum myostatin levels were independent risk factors for HCC development (adjusted hazard ratios [HRs] of age, male gender, platelet counts, and serum myostatin: 1.03, 2.79, 0.996, 1.18, respectively; all p < 0.05). Patients with high myostatin levels had a significantly higher risk of 5-year HCC development than those with low myostatin levels (HR 7.53, p < 0.001). Conclusion: Higher serum myostatin levels were significantly associated with a higher risk of developing HCC in ALC patients, which could identify high-risk patients who need stringent surveillance.Keywords
Funding Information
- Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2017R1D1A1B03031499)
- the National Research Foundation of Korea (NRF) grant funded by the Korea government (2020R1C1C1004112)
- The Research Supporting Program of The Korean Association for the Study of the Liver and The Korean Liver Foundation (None)
- 2020 Kangwon National University Hospital (None)
This publication has 44 references indexed in Scilit:
- Myostatin Gene Inactivation Prevents Skeletal Muscle Wasting in CancerCancer Research, 2014
- Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantationLiver Transplantation, 2014
- Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB–mediated mechanismProceedings of the National Academy of Sciences of the United States of America, 2013
- A Liver Full of JNK: Signaling in Regulation of Cell Function and Disease Pathogenesis, and Clinical ApproachesGastroenterology, 2012
- Muscles, exercise and obesity: skeletal muscle as a secretory organNature Reviews Endocrinology, 2012
- Increased Myostatin Activity and Decreased Myocyte Proliferation in Chronic Alcoholic CardiomyopathyAlcohol, Clinical and Experimental Research, 2011
- Elevated Myostatin Levels in Patients with Liver DiseaseAnesthesia & Analgesia, 2010
- Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged SurvivalCell, 2010
- Myostatin promotes a fibrotic phenotypic switch in multipotent C3H 10T1/2 cells without affecting their differentiation into myofibroblastsJournal of Endocrinology, 2007
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006